Table 2 EGFR Positivity by Study Subgroup
From: The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
Characteristic, n= 357 | EGFR neg | EGFR pos | P |
|---|---|---|---|
(score 0) | (score 1-3+) | Value | |
n (%) | n (%) | ||
Female, 143 | 79 (55) | 64 (45) | |
Male, 214 | 126 (59) | 88 (41) | .69 |
Age, | |||
>65, 173 | 96 (55) | 77 (45) | |
≤65, 181 | 107 (59) | 74 (41) | .698 |
ECOG performance status, | |||
0-1, 326 | 186 (57) | 140 (43) | |
2, 22 | 11 (50) | 11 (50) | .697 |
Not specified, 9 | 8 (89) | 1 (11) | |
Primary tumor location | |||
Gastroesophageal junction, 107 | 60 (56) | 47 (44) | |
Mid to distal stomach, 231 | 132 (57) | 99 (43) | .916 |
Not specified, 19 | 13 (68) | 6 (32) | |
Disease status | |||
Stage IV at diagnosis, 298 | 171 (57) | 127 (43) | |
Recurrent disease, 59 | 34 (58) | 25 (42) | 1 |
Metastatic disease sites | |||
Liver, present, 157 | 85 (54) | 72 (46) | |
Liver, not present, 199 | 119 (60) | 80 (40) | .559 |
Lymph nodes, present 219 | 127 (58) | 92 (42) | |
Lymph nodes, not present, 98 | 51 (52) | 47 (48) | .585 |
Peritoneum, present ,93 | 57 (61) | 36 (39) | |
Peritoneum, not present, 263 | 147 (56) | 116 (44) | .58 |
Lauren classification, | |||
Diffuse/mixed, 170 | 107 (63) | 63 (37) | .211 |
Intestinal, 139 | 72 (52) | 67 (48) | |
Not specified, 48 | 26 (54) | 22 (46) | |
Specimen used for EGFR testing | |||
Biopsy, 238 | 141 (59) | 97 (41) | |
Surgical specimen,116 | 62 (53) | 54 (47) | .538 |
Not specified, 3 | 2 (67) | 1 (33) | |
Primary tumor, 298 | 173 (58) | 125 (42) | |
Metastatic lesion, 50 | 24 (48) | 26 (52) | .418 |
Not specified, 9 | 9 (100) | 0 |